Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers
<h3>Background</h3> Genetic factors have a substantial role in determining development of rheumatoid arthritis (RA), and are likely to account for 50–60% of disease susceptibility. Genome-wide association studies have identified non-human leucocyte antigen RA susceptibility loci which as...
Na minha lista:
Principais autores: | Darren Plant, Edward Flynn, Hamdi Mbarek, Philippe Dieudé, François Cornélis, Lisbeth Ärlestig, Solbritt Rantapää‐Dahlqvist, GN Goulielmos, Dimitrios T. Boumpas, Prodromos Sidiropoulos, Julia S. Johansen, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland, Lars Klareskog, Andrew Filer, Christopher D. Buckley, Karim Raza, T Witte, Reinhold E. Schmidt, Jane Worthington |
---|---|
Formato: | Revisão |
Idioma: | Inglês |
Publicado em: |
2010
|
Acesso em linha: | https://doi.org/10.1136/ard.2009.121020 https://ard.bmj.com/content/annrheumdis/69/8/1548.full.pdf |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Registros relacionados
-
Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers
por: Plant, Darren, et al.
Publicado em: (2010) -
Identification of the Tyrosine-Protein Phosphatase Non-Receptor Type 2 as a Rheumatoid Arthritis Susceptibility Locus in Europeans
por: Cobb, Joanna E., et al.
Publicado em: (2013) -
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease
por: Johansson, Martin, et al.
Publicado em: (2006) -
Metabolite and Lipid Profiling of Biobank Plasma Samples Collected Prior to Onset of Rheumatoid Arthritis
por: Surowiec, Izabella, et al.
Publicado em: (2016) -
PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease.
por: Martin Johansson, et al.
Publicado em: (2005)